API | cycrimine

cycrimine (pagitane) Report issue

Small molecule Approved ^FDA

ChEMBL DrugBank Drug Central Drugs@FDA PubChem repoDB

Active Ingredient History

NOW

CYCRIMINE is an antispasmodic drug used for the treatment of Parkinson's disease (PD). It binds the muscarinic acetylcholine receptor M1, effectively reducing levels of acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of PD. ^NCATS

Chemistry

SMILES: OC(CCN1CCCCC1)(C2CCCC2)c3ccccc3
InChIKey: SWRUZBWLEWHWRI-UHFFFAOYSA-N
Mol. Mass: 287.45
ALogP: 3.94 Partition coefficient
ChEMBL Molecules:

cycrimine

cycrimine hydrochloride

More Chemistry

Pharmacology

Mechanism of Action:
- Muscarinic acetylcholine receptor M1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Oral
Pro Drug: No

Organizations (1)

Research & Development (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Parkinson Disease (approved 1953)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue